Ipilimumab with or without nivolumab in PD-1 or PD-L1 blockade refractory metastatic melanoma: a randomized phase 2 trial

VanderWalde, A; Bellasea, SL; Kendra, KL; Khushalani, NI; Campbell, KM; Scumpia, PO; Kuklinski, LF; Collichio, F; Sosman, JA; Ikeguchi, A; Victor, AI; Truong, TG; Chmielowski, B; Portnoy, DC; Chen, YB; Margolin, K; Bane, C; Dasanu, CA; Johnson, DB; Eroglu, Z; Chandra, S; Medina, E; Gonzalez, CR; Baselga-Carretero, I; Vega-Crespo, A; Garcilazo, IP; Sharon, E; Hu-Lieskovan, S; Patel, SP; Grossmann, KF; Moon, J; Wu, MC; Ribas, A

VanderWalde, A (通讯作者)，West Clin Wolf River, Germantown, TN USA.;Ribas, A (通讯作者)，Univ Calif Los Angeles, Jonsson Comprehens Canc Ctr, Los Angeles, CA USA.

NATURE MEDICINE, 2023; 29 (9): 2278

Abstract

In this randomized phase 2 trial, blockade of cytotoxic T-lymphocyte protein 4 (CTLA-4) with continuation of programmed death protein 1 (PD-1) blockad......

Full Text Link


Links

期刊讨论 | 中国SCI论文 | 期刊主页 | 投稿经验 | 杂志官网 | 投稿链接 | 作者需知 | PMC链接 | Pubmed全文检索